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EDITORIAL
Ear, nose and throat (ENT) surgery may be the 
oldest surgical specialty, but it certainly has not lost 
its lustre with age. It encompasses a wide variety 
of pathology, spanning all age groups regardless 
of gender, ethnicity or socio-economic status. The 
field of ENT (otorhinolaryngology) includes a broad range of 
procedures, often using advanced technology both at the bedside and 
in theatre. Recent decades have seen the discipline expand to include 
subspecialties like head and neck surgery, neuro-otology, anterior and 
lateral skull base surgery, allergology and paediatrics. 
In South Africa (SA), where it is very apparent that there are 
economic barriers to diagnosis and treatment, we are faced with the 
co-existence of the developing and developed world. Health budgets, 
poor infrastructure and shortage of medical staff are some of the 
challenges regularly encountered.[1] Furthermore, there are individual 
clinicians and dedicated units who strive for the best outcomes by 
pioneering ground-breaking surgeries, regardless of limitations in 
resources – including head and neck cancer units using free flaps, 
endoscopic skull-base surgery using neuro-navigation and cochlear 
implant programmes, to name a few. 
Almost 20% of general practitioner (GP) visits involve complaints 
arising from the ears, nose or throat. In the paediatric population, 
this figure rises to around 50%.[2] As of 31 March 2012, 38  236 
medical practitioners are registered with the Health Professions 
Council of South Africa (HPCSA), of whom only 0.9% are ENT 
specialists (344  practitioners).[3,4] In addition, almost 70% of the 
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44 million South Africans who utilise the public health sector are 
serviced by less than 35 full-time ENT specialists. Consequently, the 
majority of ENT problems are managed by non-ENT specialists.
The global health stage is dominated by communicable diseases 
like HIV and tuberculosis (TB). Many argue that diseases like hearing 
impairment and head and neck cancers receive less attention, despite 
being major public health concerns. In SA, communicable and non-
communicable ENT diseases are interlinked owing largely to the high 
prevalence of HIV and the increasing problem of multi-drug resistant 
(MDR) TB, together with the existing socio-economic challenges. 
SA has the highest number of HIV-infected individuals in any 
country, with the highest prevalence among people between the 
ages of 15 and 49 years.[5] Up to 100% of HIV-positive patients will 
present with head and neck manifestations.[6] Oral candidiasis and 
rhinosinusitis were traditionally documented as the most common 
ENT manifestations of HIV.[7] However, with the institution of 
antiretroviral (ARV) rollout programmes, patients may present 
differently. This has been suggested by Tshifularo et al.,[8] who 
found adenoid pathology, cervical lymphadenopathy and chronic 
suppurative otitis media to be the top three manifestations at Steve 
Biko Academic Hospital. While this may imply a change, it could be 
multi-factorial, rather than solely drug-related effects. More research 
is therefore needed from patients on long-term ARV therapy. 
According to the World Health Organization (WHO), hearing 
impairment is the greatest sensory deficit globally. There are 
360  million people worldwide suffering from disabling hearing 
loss (>40 db), more than half of whom live in low- and middle-
income countries.[9] Of greater concern is that these people may not 
be identified as having hearing loss, because there are not enough 
screening programmes in place.[9] 
Perhaps most tragic, 50% of all causes of hearing loss are preventable – 
causes that can be alleviated by early prevention techniques, including 
screening programmes and early definitive management strategies.[9]
HIV-positive people have an increased risk of developing hearing loss 
– primarily from the disease (non-iatrogenic), from opportunistic 
infections, or from the effects of drugs related to treatment.[10] 
Anti retroviral therapy (ART), alone or in combination with other 
treatments, could add to the overall toxic effect on hearing.[10] In 
SA, where the increase in MDR-TB has been linked to the HIV 
epidemic, patients on WHO-recommended MDR-TB second-line 
drug therapy are more likely to have nephrotoxicity and ototoxicity, 
the latter being permanent. [11] Some individuals may develop sudden 
profound sensorineural hearing loss following a single dose of 
aminoglycoside, highlighting the need to use it with caution even 
in routine medical practice. Harris et al. [11] found that 57% of MDR-
TB patients developed high frequency hearing loss, and that 70% of 
HIV-positive patients were more likely to develop hearing loss than 
HIV-negative patients on MDR-TB therapy. As a consequence, HIV 
and TB co-infected individuals are a high-risk population for hearing 
loss, and without awareness and intervention, may constitute a new 
deaf community in sub-Saharan Africa (SSA) – a population that will 
require audiological and ENT services.[1]
Despite SA being the most advantaged in Africa regarding access 
to audiology services, hearing aids and ENT interventions, Fagan and 
Jacobs[12] found that our country still only fulfilled less than half of 
the required service ratios compared with the UK. SA does not have 
adequate screening programmes for children, the elderly or high-risk 
populations.
The global burden of illness from chronic suppurative otitis media 
(chronic active otitis media) involves 65 - 330 million individuals 
with otorrhoea, 60% of whom suffer from significant hearing 
impairment.[13] Prevalence varies in different population groups, with 
local prevalence rates in SSA ranging between 0.4 and 4.2% – 50% of 
these cases presenting in children under 10 years.[14]
Otorrhoea is treated at a primary care level in SA, and patients 
are generally referred to specialists only after treatment failure. 
Tiedt et al.[14] and Meyer et al.,[15] undertaking local studies at different 
centres, highlight the delay in patients being referred to ENT services. 
In children who suffer associated hearing loss this delay has a 
negative impact on school performance.[14]
In addition, Loock[16] and the aforementioned two local ENT 
departments investigated the microbial spectrum of otorrhoea 
in their respective communities.[14-17] All of the local studies have 
identified Proteus mirabilis and Pseudomonas aeruginosa as the most 
prevalent pathogens. This differs from findings elsewhere in the world. 
Guidelines for the management of otitis media, aimed at a primary 
healthcare level, were released by the the National Department of 
Health in 2012. [18] Although very comprehensive, the recommended 
antimicrobials (topical or systemic), including oral amoxicillin, for 
chronic otorrhoea (non-responders) do not cover the majority of 
organisms encountered. However, topical fluoroquinolone eardrops 
with ear mopping covers 95% of organisms cultured and is not 
ototoxic. Should the first-line treatment fail then an antibiotic group 
with Gram-negative cover should be considered.[15] 
Patient profiles, disease projection and response to treatment all 
vary according to the location and population. In many spheres of 
medicine, we rely heavily on international sources, often adapting 
protocols and guidelines for local use. The above findings emphasise 
the need to promote local research. 
Ideally, smaller surgical disciplines like ENT should capture data 
at local institutions and keep national registries for specific diseases. 
In doing so, the burdens of disease can be better managed, and local 
databases can also be used for auditing local services. Research 
should be integrated – across institutions, between disciplines, across 
departments and beyond economic barriers into the private sector 
– where pioneering work often goes unpublished. Comparative 
assessments of local versus international findings are also necessary, 
thereby facilitating a global perspective for SA ENT centres that will 
enable them to improve and compete with world leaders in the field.
Head and neck squamous cell cancer (HNSCC) is the sixth most 
common malignancy and the eighth leading cause of cancer death 
worldwide.[19] The incidence in the developing world is on the rise – 
attributable to increased life expectancy from communicable disease 
control, excess tobacco and alcohol consumption (risk factors for 
head and neck cancers) and HIV. [1] Treatment outcomes for patients 
treated in developing world versus developed world countries are quite 
different. Farmer et al.[20] found an association between cancer fatality 
rates and national income – the cancer case fatality rate in low-income 
countries is 75%, as opposed to 45% in high-income countries.
HNSCC is also the third most common head and neck malignancy 
for patients with HIV (after Kaposi’s sarcoma and non-Hodgkin’s 
lymphoma).[21] Although not an AIDS-defining illness, HNSCC is 
seen in excess among HIV-infected individuals, and is sometimes 
referred to an ‘opportunistic’ cancer. Patients with a suspicious 
persistent head and neck lesion should always be referred for further 
investigation.
In addition, there is growing evidence that confirms the causative 
relationship between oncogenic human papillomavirus (HPV) and 
oropharyngeal squamous carcinoma in the general population. The 
prevalence of HPV in oropharyngeal cancer, especially tonsillar 
cancer, is as high as 90%. HPV type 16 is most commonly involved. 
An unexpected and positive finding in the literature is HPV-positive 
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HNSCC being associated with high-stage tumours, but actually 
having better survival.[21] 
There are many challenges that face ENT specialists – as clinicians 
who value contribution to individual patients, and in the broader 
field of population health. Issues highlighted in this editorial help 
give insight into the current ENT perspective, notwithstanding other 
important topics that have not been addressed. 
The SA Society of Otorhinolaryngology, Head and Neck Surgery 
is well established and includes private and public specialists, as well 
as registrars in training. Also established is the National Registrar 
Society, a subsidiary body that is managed independently by elected 
registrars and includes a national database and interactive website. 
Both divisions are actively committed to maintaining a high standard 
of training.
S Peer
Department of Otorhinolaryngology, University of Cape Town, South 
Africa, and Clinical Research Fellow, Department of ENT, SickKids 
Hospital, Toronto, Canada
Corresponding author: S Peer (shaziapeer@gmail.com)
1. Fagan JJ. Developing world ENT: A global responsibility. J Laryngol Otol 2012;126(6):544-547. [http://
dx.doi.org/10.1017/S0022215112000345] 
2. Clamp PJ, Gunasekaran S, Pothier DD, Saunders MW. ENT in general practice: Training, experience and 
referral rates. J Laryngol Otol 2007;121(6):580-583. [http://dx.doi.org/10.1017/S0022215106003495]
3. HPCSA. iRegister. http://iregister.hpcsa.co.za/RegisterSearch.aspx (accessed 4 June 2013).
4. HPCSA. Statistics. http://www.hpcsa.co.za/statistics.php (accessed 4 June 2013).
5. UNAIDS. UNAIDS report on the global epidemic. Geneva: UNAIDS, 2010. http://www.unaids.org/
globalreport/global_report.htm (accessed 4 June 2013).
6. Tami TA, Hairston JA. HIV and otolaryngology. In: Gleeson M, ed. Scott-Brown’s Otorhinolaryngology, 
Head and Neck Surgery. London: Hodder Arnold, 2008:238-250.
7. Lubbe DE. HIV and ENT. CME 2004;22:250-253.
8. Tshifularo M, Govender L, Monama G. Otolaryngological, head and neck manifestations in HIV-infected 
patients seen at Steve Biko Academic Hospital in Pretoria, South Africa. S Afr Med J 2013;103(7):464-
466. [http://dx/doi.org/10.7196/SAMJ.6786]
9. World Health Organization. Deafness and hearing loss. Geneva: WHO, 2013. http://www.who.int/
mediacentre/factsheets/fs300/en/index.html (accessed 12 June 2013).
10. Khoza-Shangase K. Is there a need for ototoxicity monitoring in patients with HIV/AIDS? African 
Journal of Pharmacy & Pharmacology 2010;4(9):574-579.
11. Harris, T, Bardien S, Schaaf HS, et al. Aminoglycoside-induced hearing loss in HIV-positive and HIV-
negative multidrug-resistant tuberculosis patients. S Afr Med J 2012;102(6):363-366. 
12. Fagan JJ, Jacobs M. Survey of ENT services in Africa: Need for a comprehensive intervention. Global 
Health Action 2009;2:e1-e7. [http://dx.doi.org/10.3402/gha.v2i0.1932]
13. WHO. Chronic suppurative otitis media. Burden of illness and management options. Geneva: WHO, 
2004. http://www.who.int/pbd/deafness/activities/hearing_care/otitis_media.pdf (accessed 4 June 
2013).
14. Tiedt NJ, Butler IR, Hallbauer UM, et al. Paediatric chronic suppurative otitis media in the Free 
State Province: Clinical and audiological features. S Afr Med J 2013;103(7):467-470. [http://dx/doi.
org/10.7196/SAMJ.6636]
15. Meyer E, Whitelaw A, Edkins O, Fagan JJ. Chronic otorrhoea: Spectrum of microorganisms and 
antibiotic sensitivity in a South African cohort. S Afr Med J 2013;103(7):471-473. [http://dx/doi.
org/10.7196/SAMJ.6066]
16. Loock JW. A randomised controlled trial of active chronic otitis media comparing courses of eardrops 
v. one-off topical treatments suitable for primary, secondary and tertiary healthcare settings. Clin 
Otolaryngol 2012;37(4):261-270. [http://dx.doi.org/10.1111/j.1749-4486.2012.02532.x]
17. Seedat RY, Bester A, Möller E, et al. Bacteriology of chronic suppurative otitis media in the era of 
ototopical quinolone use. 42nd Annual Congress of the South African Society of Otorhinolaryngology-
Head and Neck Surgery. Cape Town, 8-11 October 2006.
18. South African Department of Health. National Guidelines for the Management of Otitis Media. 
Pretoria: DoH. http://www.doh.gov.za/docs/policy/2012/hearingguide.pdf (accessed 4 June 2013). 
19. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-
108. [http://dx.doi.org/10.3322/canjclin.55.2.74]
20. Farmer P, Frenk J, Knaul FM, et al. Expansion of cancer care and control in countries of low and middle income: 
A call to action. Lancet 2010;376(9747):1186-1193. [http://dx.doi.org/10.1016/S0140-6736(10)61152-X]
21. McLemore ML, Haigentz Jr M, Smith RV, et al. Head and neck squamous cell carcinomas in HIV-positive 
patients: A preliminary investigation of viral associations. Head Neck Pathol 2010;4(2):97-105. [http://
dx.doi.org/10.1007/s12105-010-0171-9]
S Afr Med J 2013;103(7):455-457. DOI:10.7196/SAMJ.7121
